AJI Capital
VC Fund
Huntington, United States
AJI Capital is an entrepreneur led early stage venture firm focused on bringing seed capital to start up organizations. Leveraging hands on experience within a start up environment, AJI Capital’s team provides exponential value to entrepreneurs beyond its investment.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries AJI Capital invests in
Stages AJI Capital invests in
Countries AJI Capital invests in
Investment Focus
Industry
- Software 3 (38%)
- Health Care 3 (38%)
- Machine Learning 2 (25%)
- Health Diagnostics 2 (25%)
- Artificial Intelligence 2 (25%)
Stage
- Seed 4 (50%)
- Funding Round 2 (25%)
- Pre-Seed 1 (13%)
- Series B 1 (13%)
Country
- United States 5 (63%)
- Turkey 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cypien AI
|
Cypien AI is an artificial intelligence system that provides personalized experiences by converting simple web pages into an active and modular business platform. | Pre-Seed / Jun 25, 2026 | |
Digitouch Health
|
Digitouch Health aids in the management of cardiovascular health and can collaborate with healthcare practitioners to help people live longer, healthier lives. It is based in Valhalla, New York. | Seed / Jan 01, 2018 | |
Wylei
|
Wylei provides adaptive content solutions to agencies and brands to increase digital messaging relevance and engagement. It uses advanced predictive algorithms to take the guesswork out of digital web, email, mobile, and video campaigns. Wylei's Adaptive Content(TM) and Predictive Intelligence, delivers emails that adapt to the specificcontext of open, based on where, how, and when the email is viewed. | $1.5M / Dec 14, 2017 | |
PainQx
|
PainQx is a diagnostic/software company that has developed a next generation approach to objectively measure pain in humans. The PainQx platform achieves this by assessing neural activity from a patient’s brain and processing and decoding the data through proprietary algorithms. The output is a scaled pain and neurological side effectsbiomarker that is directly correlated to a patient’s pain state. The PainQx system is currently being used as a clinical assessment tool by companies using pain as a primary or secondary clinical end point to measure their drug’s and/or device’s efficacy. | $1.6M / Aug 28, 2017 | |
|
PainQx
|
PainQx is a diagnostic/software company that has developed a next generation approach to objectively measure pain in humans. The PainQx platform achieves this by assessing neural activity from a patient’s brain and processing and decoding the data through proprietary algorithms. The output is a scaled pain and neurological side effectsbiomarker that is directly correlated to a patient’s pain state. The PainQx system is currently being used as a clinical assessment tool by companies using pain as a primary or secondary clinical end point to measure their drug’s and/or device’s efficacy. | $1.6M / Seed / Aug 28, 2017 | |
Commerce Signals
|
Commerce Signal unlock merchant acquirer payment data for use in media measurement.To develop a new data-sharing model, Tom Noyes (the Founder), partnered with Russ Schrader, the former Chief Privacy Officer of Visa and a member of the Department of Homeland Security’s Data Privacy Committee. Together they designed a model, Federated Data, thatenables insight sharing between businesses without losing control of the data or sacrificing consumer privacy.Commerce Signals was founded in 2014 to bring better, unique payment data sets to the market at speed and in a privacy-centric manner. | $12M / Series B / Jul 17, 2017 | |
ENB Therapeutics
|
ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Its lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis, and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time-efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.Its products, as combination therapy with immuno-oncology agents, create a new and superior standard of care that blocks key mechanisms of drug resistance, stimulates the immune system to fight cancer, and prevents cancer from spreading.ENB Therapeutics was founded in 2015 and is headquartered in New York, New York. | $110K / Seed / Mar 10, 2017 | |
Mymee
|
Mymee is a remote care and support services company for people struggling with incurable rheumatic and neurological autoimmune diseases. Mymee programs combine expert health coaching, trigger identification and personalized care plans to reduce disease flares based on each individual's unique diet, lifestyle and environmental triggers. Resultswith Mymee in a randomly controlled trial demonstrated clinically significant improvements in 9 out of 10 health-related quality of life domains, including fatigue and pain among others. | Seed / Jan 01, 2017 |
Co-Investors
Accelerate New York Seed Fund
4 deals together
Arizona Tech Investors
2 deals together
MassChallenge
2 deals together
Mid Atlantic Bio Angels
2 deals together
New York Angels
2 deals together
NYU Innovation Venture Fund
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does AJI Capital invest in?
AJI Capital invests primarily in Software, Health Care and Machine Learning startups, most often at Seed and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did AJI Capital last invest?
The most recent investment recorded for AJI Capital closed in Jun 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
